Author:
Ali Farihah,Russell Cayley,Greer Alissa,Bonn Matthew,Werb Daniel,Rehm Jürgen
Abstract
Abstract
Background
In May 2022, Health Canada approved a three-year exemption from the Controlled Drugs and Substances Act decriminalizing possession of certain illegal substances for personal use among adults in the province of British Columbia. The exemption explicitly includes a cumulative threshold of 2.5 g of opioids, cocaine, methamphetamine, and MDMA. Threshold quantities are commonly included in decriminalization policies and justified within law enforcement systems to delineate personal use among people who use drugs versus drug dealers who are carrying for trafficking purposes. Understanding the impact of the 2.5g threshold can help define the extent to which people who use drugs will be decriminalized.
Methods
From June-October 2022, 45 people who use drugs from British Columbia were interviewed to gain an understanding of their perceptions on decriminalization, particularly on the proposed threshold of 2.5 g. We conduced descriptive thematic analyses to synthesize common interview responses.
Results
Results are displayed under two categories: 1) Implications for substance use profiles and purchasing patterns, including implications on the cumulative nature of the threshold and impacts on bulk purchasing, and 2) Implications of police enforcement, including distrust of police use of discretion, potential for net widening and jurisdictional discrepancies in enforcing the threshold. Results illustrate the need for the decriminalization policy to consider diversity in consumption patterns and frequency of use among people who use drugs, the inclination to purchase larger quantities of substances for reduced costs and to guarantee a safe and available supply, and the role police will play in delineating between possession for personal use or trafficking purposes.
Conclusions
The findings underscore the importance of monitoring the impact of the threshold on people who use drugs and whether it is countering the goals of the policy. Consultations with people who use drugs can help policymakers understand the challenges they may face when trying to abide by this threshold.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Health Policy
Reference41 articles.
1. Government of Canada. Opioid- and stimulant-related harms in Canada. Ottawa: Government of Canada; 2022.
2. Russell C, Law J, Bonn M, Rehm J, Ali F. The increase in benzodiazepine-laced drugs and related risks in Canada: the urgent need for effective and sustainable solutions. Int J Drug Policy. 2023;111: 103933.
3. B.C. Coroners Service. BC Coroners service death review panel: a review of illicit drug toxicity deaths. Vancouver: BC Coroner's Service; 2022.
4. B.C. Coroners Service. Illicit drug toxicity deaths in BC: January 1 2011 - December 31, 2021. Vancouver: Government of BC; 2022.
5. Virani HN, Haines-Saah RJ. Drug decriminalization: A matter of justice and equity, not just health. Am J Prev Med. 2020;58(1):161–4.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献